Putney is a rapidly growing pharmaceutical company focused on the development and sale of FDA approved generic prescription medicines for pets, especially where cost is a barrier to prescribing, compliance or use. Our mission is to bring fairly priced, high quality generic pet medicines to the market so that pet owners and veterinarians can make pet healthcare decisions based on what a pet needs,
rather than what a pet owner can afford. Putney has invested $50million in R&D and we believe we have the largest pipeline in advanced stages of development and under review at the FDA of any company in animal health, including brand and other generic companies. Putney has already launched nine FDA approved veterinary generics, including four first-to-market generics with the same dosage form as the brand. Putney is built on trust and respect, high ethical standards, high quality products, and on confidential relationships with our industry partners. We are energized by the fact that we are doing something that no other company has done and, as pet owners and pet lovers, we are motivated by the fact that we are bringing the benefits of generics to pet healthcare.
